View More Recent Stories

Jun 2, 2023 08:33AM Kiora Pharmaceuticals (KPRX) Prices $5M Share Offering at $1.10/sh
Jun 2, 2023 08:30AM Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
May 9, 2023 07:00AM Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
May 1, 2023 07:02AM Kiora Pharmaceuticals (KPRX) Presents Encore Imaging Results of KIO-301
May 1, 2023 07:00AM Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting
Apr 27, 2023 02:55PM Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind
Apr 26, 2023 07:03AM Kiora Pharmaceuticals' (KPRX) KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects
Apr 26, 2023 07:00AM Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects
Apr 21, 2023 07:03AM Kiora Pharmaceuticals (KPRX) Appoints Mark Pennesi to its Board
Apr 21, 2023 07:00AM Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
Apr 17, 2023 07:00AM Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases
Mar 30, 2023 07:00AM Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting
Mar 23, 2023 07:03AM Kiora Pharmaceuticals (KPRX) Reports FY22, Provides Update on Clinical Development Progress
Mar 23, 2023 07:00AM Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress
Mar 10, 2023 07:00AM Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting
Feb 14, 2023 04:10PM Groundbreaking clinical trial underway to improve vision in individuals with advanced Retinitis Pigmentosa (RP)
Feb 7, 2023 07:02AM Kiora Pharmaceuticals (KPRX) Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases
Feb 7, 2023 07:00AM Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases
Feb 3, 2023 07:01AM Kiora Pharmaceuticals (KPRX) Enters Equity Purchase Agreements with Lincoln Park Capital
Feb 3, 2023 07:00AM Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital
Jan 9, 2023 07:03AM Kiora Pharmaceuticals (KPRX) Highlights Anticipated Clinical and Corporate Milestones for 2023
Jan 9, 2023 07:00AM Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website
Jan 3, 2023 07:01AM Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023
Nov 18, 2022 08:31AM Kiora Pharmaceuticals (KPRX) to Raise $3.12M From Warrant Exercise
Nov 18, 2022 08:30AM Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants
Nov 17, 2022 06:45AM Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa
Nov 9, 2022 06:45AM Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End
Oct 17, 2022 08:04AM Kiora Pharmaceuticals (KPRX) Announces Publication of Phase 1 Trial Results for KIO-100
Oct 17, 2022 08:00AM Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease
Oct 13, 2022 06:48AM Kiora Pharmaceuticals (KPRX) Regains Nasdaq Compliance
Oct 13, 2022 06:45AM Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
Sep 26, 2022 06:46AM Kiora Pharmaceuticals (KPRX) Announces 1:40 Reverse Stock Split
Sep 26, 2022 06:45AM Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split
Sep 13, 2022 06:45AM Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance
Aug 12, 2022 06:45AM Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results
Jul 28, 2022 06:48AM Kiora Pharmaceuticals (KPRX) Issued US Patent Covering KIO-201
Jul 28, 2022 06:45AM Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics
Jul 26, 2022 04:38PM Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Jul 22, 2022 08:32AM Kiora Pharmaceuticals (KPRX) Prices $5.2 Million Underwritten Public Offering
Jul 22, 2022 08:30AM Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering
Jul 5, 2022 06:45AM Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial Defects
View More Recent Stories